{
    "clinical_study": {
        "@rank": "153105", 
        "arm_group": [
            {
                "arm_group_label": "nepafenac", 
                "arm_group_type": "Experimental", 
                "description": "Nepafenac 0.1% eye drops, 3 times a day"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "No Intervention", 
                "description": "No intervention in the control arm"
            }
        ], 
        "brief_summary": {
            "textblock": "The Nevanac product information insert says that it can cause increase in eye pressure in\n      5-10% of patients. There is very little published literature on the effect of topical\n      Nepafenac eye drops on eye pressure in normal people. The purpose of our study is to report\n      this effect  with a working hypothesis that there is no increase in eye pressure following\n      use of Nepafenac eye drops."
        }, 
        "brief_title": "Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Intraocular Pressure", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Best corrected visual acuity better than 20/80 in both eyes\n\n          -  Intraocular pressure  \u226421 mmHg in both eyes\n\n          -  Open angles on 4 mirror gonioscopy without indentation\n\n          -  Normal optic disc on stereoscopic examination and photographs\n\n        Exclusion Criteria:\n\n          -  Change in the systemic medication profile during the course of the study\n\n          -  Allergy to nepafenac molecule\n\n          -  Corneal thinning/corneal infections\n\n          -  Any intraocular surgery in past 3 months\n\n          -  Pregnancy or those planning to conceive\n\n          -  Breast feeding patients\n\n          -  Unwillingness to participate in the trial\n\n          -  Concomitant use of any other ocular drug (except artificial tears)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "327", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995890", 
            "org_study_id": "TVPEI"
        }, 
        "intervention": {
            "arm_group_label": "nepafenac", 
            "intervention_name": "nepafenac", 
            "intervention_type": "Drug", 
            "other_name": "Nevanac"
        }, 
        "intervention_browse": {
            "mesh_term": "Tetrahydrozoline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "nepafenac eye drops", 
            "intraocular pressure"
        ], 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Vadodara", 
                    "country": "India", 
                    "state": "Gujarat", 
                    "zip": "390001"
                }, 
                "name": "Dr TV Patel Eye Insititute"
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Nepafenac Eye Drops on Intraocular Pressure - a Randomized Prospective Study", 
        "overall_official": {
            "affiliation": "TV Patel Eye Institute", 
            "last_name": "Paaraj R Dave, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Intraocular pressure elevation of more than 4 mmHg from baseline", 
                "measure": "Intraocular pressure", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Intraocular pressure elevation of more than 4 mmHg from baseline", 
                "measure": "Intraocular pressure", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "reference": {
            "PMID": "10850857", 
            "citation": "Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995890"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "16488953", 
                "citation": "Chiba T, Kashiwagi K, Chiba N, Tsukahara S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2006 Mar;90(3):314-7."
            }, 
            {
                "PMID": "18664937", 
                "citation": "Warren KA, Fox JE. Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients. Retina. 2008 Nov-Dec;28(10):1427-34. doi: 10.1097/IAE.0b013e31817e7ead."
            }
        ], 
        "source": "Dr T V Patel Eye Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dr T V Patel Eye Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}